AIM: In schizophrenia, metabolic syndrome incidence is double that of the general population, with women having a higher incidence. Pharmacogenetically regulated folic acid may be related to this risk. DNA methylation and metabolic syndrome within this group has not been previously studied. METHODS: Metabolic syndrome was evaluated with fasting laboratory measurements, and dietary and lifestyle assessments. Methylation analysis used a peripheral sample for the LINE-1 assay. DNA was also genotyped for MTHFR 677C/T. RESULTS: This analysis included 133 subjects. We found a significant relationship between LINE-1 methylation, and an interaction between MTHFR and gender, controlling for serum folate (p = 0.008). Females with the 677TT genotype had the lowest methylation (56%) compared with the other groups (75%). CONCLUSION: TT genotype females had the lowest methylation, which may explain metabolic syndrome gender differences in schizophrenia. Folate supplementation may be a suggested intervention within schizophrenia; however, additional work is required.
AIM: In schizophrenia, metabolic syndrome incidence is double that of the general population, with women having a higher incidence. Pharmacogenetically regulated folic acid may be related to this risk. DNA methylation and metabolic syndrome within this group has not been previously studied. METHODS:Metabolic syndrome was evaluated with fasting laboratory measurements, and dietary and lifestyle assessments. Methylation analysis used a peripheral sample for the LINE-1 assay. DNA was also genotyped for MTHFR677C/T. RESULTS: This analysis included 133 subjects. We found a significant relationship between LINE-1 methylation, and an interaction between MTHFR and gender, controlling for serum folate (p = 0.008). Females with the 677TT genotype had the lowest methylation (56%) compared with the other groups (75%). CONCLUSION: TT genotype females had the lowest methylation, which may explain metabolic syndrome gender differences in schizophrenia. Folate supplementation may be a suggested intervention within schizophrenia; however, additional work is required.
Authors: Ruud van Winkel; Bart P Rutten; Odette Peerbooms; Joseph Peuskens; Jim van Os; Marc De Hert Journal: Schizophr Res Date: 2010-06-12 Impact factor: 4.939
Authors: Vicki L Ellingrod; Del D Miller; Stephan F Taylor; Jessica Moline; Timothy Holman; Jane Kerr Journal: Schizophr Res Date: 2007-10-31 Impact factor: 4.939
Authors: Joshua L Roffman; Adam Z Nitenson; Yigal Agam; Marlisa Isom; Jesse S Friedman; Kara A Dyckman; David G Brohawn; Jordan W Smoller; Donald C Goff; Dara S Manoach Journal: PLoS One Date: 2011-09-28 Impact factor: 3.240
Authors: J Richard Pilsner; Howard Hu; Adrienne Ettinger; Brisa N Sánchez; Robert O Wright; David Cantonwine; Alicia Lazarus; Héctor Lamadrid-Figueroa; Adriana Mercado-García; Martha Maria Téllez-Rojo; Mauricio Hernández-Avila Journal: Environ Health Perspect Date: 2009-03-25 Impact factor: 9.031
Authors: Rebecca K Simmons; Sara A Stringfellow; Matthew E Glover; Anjali A Wagle; Sarah M Clinton Journal: Brain Res Date: 2013-08-14 Impact factor: 3.252
Authors: Gabriel Oh; Sun-Chong Wang; Mrinal Pal; Zheng Fei Chen; Tarang Khare; Mamoru Tochigi; Catherine Ng; Yeqing A Yang; Andrew Kwan; Zachary A Kaminsky; Jonathan Mill; Cerisse Gunasinghe; Jennifer L Tackett; Irving I Gottesman; Gonneke Willemsen; Eco J C de Geus; Jacqueline M Vink; P Eline Slagboom; Naomi R Wray; Andrew C Heath; Grant W Montgomery; Gustavo Turecki; Nicholas G Martin; Dorret I Boomsma; Peter McGuffin; Rafal Kustra; Art Petronis Journal: Biol Psychiatry Date: 2014-07-01 Impact factor: 13.382